An2 Therapeutics Inc. has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron-containing small molecules for the treatment of tuberculosis (TB) and malaria.
Researchers from Michigan State University and Tarn Biosciences Inc. have published their work on the discovery and preclinical evaluation of novel antimycobacterial nitro-containing compounds.
Centre Hospitalier Regional Universitaire de Lille and Centre National de la Recherche Scientifique have patented norbornene analogues reported to be useful for the treatment of tuberculosis.
In a recent publication, researchers from Institute of Medicinal Biotechnology and affiliated organizations described a novel group of antitubercular agents with an improved safety profile.
Tuberculosis (TB) is the 13th leading cause of death in the world, and it is rising together with the increased prevalence of drug-resistant TB in many countries. The Bacille Calmette-Guerin (BCG) vaccine is the only available TB vaccine, and it has been given to more people than any other vaccine. While the BCG vaccine has saved tens of millions of lives, it confers suboptimal protection against pulmonary TB as it is limited to providing protection only until early childhood. Significantly, the BCG vaccine is administered intradermally to confer exceptional mucosal immunity as compared to most other vaccines, which are more commonly administered intramuscularly. Novel strategies to improve the duration of TB mucosal immunity are urgently needed.
Research at Middle Tennessee State University has led to the development of peptoids reported to be useful for the treatment of fungal infections and tuberculosis.
Prior to the COVID-19 pandemic, tuberculosis ranked as the leading cause of infectious disease deaths worldwide; the increase of multidrug-resistant Mycobacterium tuberculosis puts some pressure on the search for new tuberculosis therapeutic approaches. Researchers from Sanofi SA and their collaborators have published preclinical results on a sequanamycin – sequanamycin 9 (SEQ-9) – for the potential treatment of tuberculosis.
Calibr at Scripps Research and the Bill & Melinda Gates Medical Research Institute (Gates MRI) have entered into a strategic licensing agreement to advance development of a novel investigational compound for treatment of tuberculosis (TB).
State University of New Jersey and Tufts University have patented compounds with ability to modulate Mycobacterium tuberculosis (Mtb) response to high environmental chloride and acidic pH for Mtb growth inhibition reported to be useful for the treatment of tuberculosis.
